Key result
The frequency of HLA-DR4 was similar between patients with rheumatic heart disease and healthy controls (30% vs 23%), failing to corroborate previously reported associations.
Why the study?
Is there an association between specific HLA-DR types (DR2, DR4, DRw53) and rheumatic, congenital, or degenerative cardiac valve diseases in Saudi patients?
Case-Control (n=202)
Is there an association between specific HLA-DR types (DR2, DR4, DRw53) and rheumatic, congenital, or degenerative cardiac valve diseases in Saudi patients?
Absolute Event Rate: 30% vs 23%
This study found no significant association between HLA-DR4 and rheumatic heart disease in Saudi patients, challenging previous findings based on serotyping.
No HLA-DR4 link to rheumatic heart disease in this cohort; challenges prior associations and leaves genetic markers unresolved for future study.
Subjects of Saudi origin were DNA typed for HLA-DR2, DR4 and DRw53 by amplification fragment-length polymorphism and amplification by sequence-specific primer techniques based on polymerase chain reaction. Of these subjects, 125 had sporadic heart valve disease (96 with rheumatic heart disease, 18 with degenerate and 11 with congenital degenerate valve disease) and 77 were healthy Saudi blood donors. While the frequency of individuals typed DR4 was about the same in the rheumatic heart disease as in the control category (30% versus 23%, respectively), it was found to be higher (55%; P<0.02), but below the level of marginal significance after correcting for the number of DR types, in the congenital degenerate valve category. No preferential association of any DR4 subtype could be detected. The incidence of DR2 was lower in the congenital cases compared to that in the controls (9% versus 21%) and remained about the same in the rheumatic heart disease patients as in the controls. The frequency of DRw53 in the degenerate valve categories was slightly lower than that in the controls, but the difference was not significant. The study failed to corroborate the association between HLA-DR4 and rheumatic heart disease shown in previous studies using the serotyping approach.
No takes yet. Share an insight, caveat, or question.
Butt et al. (1997) conducted a case-control in Cardiac valve diseases (rheumatic, congenital, degenerative) (n=202). HLA-DR4 vs. Healthy controls was evaluated on Frequency of HLA-DR4 in rheumatic heart disease. The frequency of HLA-DR4 was similar between patients with rheumatic heart disease and healthy controls (30% vs 23%), failing to corroborate previously reported associations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: